Literature DB >> 32462631

Quantitative Assessment of Cardiac Hypermetabolism and Perfusion for Diagnosis of Cardiac Sarcoidosis.

Robert J H Miller1,2, Sebastien Cadet1, Payam Pournazari2, Adele Pope1, Evan Kransdorf3, Michele A Hamilton3, Jignesh Patel3, Sean Hayes1, John Friedman1, Louise Thomson1, Balaji Tamarappoo1, Daniel S Berman1, Piotr J Slomka4.   

Abstract

BACKGROUND: Quantitative assessment of cardiac hypermetabolism from 18Flourodeoxy glucose (FDG) positron emission tomography (PET) may improve diagnosis of cardiac sarcoidosis (CS). We assessed different approaches for quantification of cardiac hypermetabolism and perfusion in patients with suspected CS. METHODS AND
RESULTS: Consecutive patients undergoing 18FDG PET assessment for possible CS between January 2014 and March 2019 were included. Cardiac hypermetabolism was quantified using maximal standardized uptake value (SUVMAX), cardiometabolic activity (CMA) and volume of inflammation, using relative thresholds (1.3× and 1.5× left ventricular blood pool [LVBP] activity), and absolute thresholds (SUVMAX > 2.7 and 4.1). Diagnosis of CS was established using the Japanese Ministry of Health and Wellness criteria. In total, 69 patients were studied, with definite or possible CS in 29(42.0%) patients. CMA above 1.5× LVBP SUVMAX had the highest area under the receiver operating characteristic curve (AUC 0.92). Quantitative parameters using relative thresholds had higher AUC compared to absolute thresholds (p < 0.01). Interobserver variability was low for CMA, with excellent agreement regarding absence of activity (Kappa 0.970).
CONCLUSIONS: Quantitation with scan-specific thresholds has superior diagnostic accuracy compared to absolute thresholds. Based on the potential clinical benefit, programs should consider quantification of cardiac hypermetabolism when interpreting 18F-FDG PET studies for CS.
© 2020. American Society of Nuclear Cardiology.

Entities:  

Keywords:  Cardiac sarcoidosis; cardiometabolic activity; positron emission tomography; quantitative analysis; sarcoid

Mesh:

Substances:

Year:  2020        PMID: 32462631     DOI: 10.1007/s12350-020-02201-5

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  2 in total

1.  Identification of cardiac sarcoidosis with (13)N-NH(3)/(18)F-FDG PET.

Authors:  Hiroyuki Yamagishi; Naoya Shirai; Masahiko Takagi; Minoru Yoshiyama; Kaname Akioka; Kazuhide Takeuchi; Junichi Yoshikawa
Journal:  J Nucl Med       Date:  2003-07       Impact factor: 10.057

Review 2.  Cardiac sarcoidosis-state of the art review.

Authors:  Edward Hulten; Saira Aslam; Michael Osborne; Siddique Abbasi; Marcio Sommer Bittencourt; Ron Blankstein
Journal:  Cardiovasc Diagn Ther       Date:  2016-02
  2 in total
  2 in total

1.  Association of high serum soluble interleukin 2 receptor levels with risk of adverse events in cardiac sarcoidosis.

Authors:  Yuta Kobayashi; Takuma Sato; Toshiyuki Nagai; Kenji Hirata; Satonori Tsuneta; Yoshiya Kato; Hirokazu Komoriyama; Kiwamu Kamiya; Takao Konishi; Kazunori Omote; Hiroshi Ohira; Kohsuke Kudo; Satoshi Konno; Toshihisa Anzai
Journal:  ESC Heart Fail       Date:  2021-09-12

2.  Diagnostic and prognostic value of Technetium-99m pyrophosphate uptake quantitation for transthyretin cardiac amyloidosis.

Authors:  Robert J H Miller; Sebastien Cadet; Darren Mah; Payam Pournazari; Denise Chan; Nowell M Fine; Daniel S Berman; Piotr J Slomka
Journal:  J Nucl Cardiol       Date:  2021-03-10       Impact factor: 5.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.